TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2018

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.

Margaretha G M Roemer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.